688202.SS
688202.SS
CNE100003NQ8
SHANGHAI MEDICILON INC
Loading chart...

Company Profile

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow chemistry, carbohydrate chemistry, analytical chemical, ADME/DMPK, pharmacology, safety assessment, IND-Enabling studies, and advanced technology services. The company also provides peptide, SiRNA, ADC, Protac, AOCs, NAMs Platforms. The company was founded in 2004 and is based in Shanghai, China.

Related stocks

9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
688105.SS
688105.SS • China
NANJING VAZYME BIOTECH CO LTD
26.6 CNY
2.06B USD 1Y +49.7%
600201.SS
600201.SS • China
JINYU BIO-TECHNOLOGY CO LTD
11.84 CNY
1.95B USD 1Y +21.7%
688520.SS
688520.SS • China
SINOCELLTECH GROUP LTD
36.22 CNY
2.55B USD 1Y -35.8%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
9688.HK
9688.HK • China
ZAI LAB
19.25 HKD
2.75B USD 1Y -26.5%
1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
ZLAB
ZLAB • China
Zai Lab Limited
24.99 USD
2.81B USD 1Y -26.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
63.3% p.a.
Max Drawdown (5Y)
-93.7%
Sharpe Ratio (5Y)
-0.37
Beta Factor
0.83
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
🔴 High valuation risk: Avg P/E of 47.1 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (63.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -93.7% in the extended horizon.
ende